Beamion Lung 1: Zongertinib (BI 1810631) in Advanced HER2+ NSCLC
Edgardo Santos, MD, FACP, FCCP, provides insights into the innovative Beamion Lung 1 trial, focused on assessing the safety and tolerability of zongertinib (BI 1810631) in patients with advanced, previously treated HER2+ non-small cell lung cancer (NSCLC).
EP: 1.Beamion Lung 1: Zongertinib (BI 1810631) in Advanced HER2+ NSCLC
EP: 2.Expert Analysis on Recent Developments in DESTINY-Lung01 and DESTINY-Lung02 Trials
EP: 3.Expert Perspectives on the Latest TROPION-Lung01 Data
EP: 4.EMPOWER-Lung3: Cemiplimab Plus Chemotherapy in Advanced NSCLC
EP: 5.EMPOWER-Lung1 and 3 Squamous Subgroup Analysis: Expert Insights
EP: 6.Future Perspectives on the Treatment of NSCLC
This is a video synopsis/ summary of an OncLive Insights® featuring Edgardo S. Santos, MD, FACP, FCCP.
Edgardo S. Santos, MD, FACP, FCCP, discussed recent advances in non–small cell lung cancer (NSCLC) from the 2023 World Conference on Lung Cancer in Singapore and the European Society of Medical Oncology Congress 2023 in Madrid, Spain. He highlighted results from the BEAMION Lung 1 trial that evaluated zongertinib, a new tyrosine kinase inhibitor for treating patients with HER2 mutations.
The phase 1 portion had an overall response rate of approximately 45% and a disease control rate of 91% in patients with NSCLC, including those with HER2 exon 20 insertions. No maximum tolerated dose was reached, with only grade 3 elevations in alanine aminotransferase and aspartate aminotransferase observed. The phase 1b results confirmed efficacy, with a 75% response rate and greater than 90% disease control rate. Further research is warranted given the favorable safety profile and efficacy signals with zongertinib in early phase NSCLC trials.
Video synopsis is AI-generated and reviewed by OncLive® editorial staff.
